⌘K
t
Creo Medical Group plc announced on 09 July 2025 that its Board, following consultation with significant shareholders, revised the exercise price of options granted to certain PDMRs. The Company agreed with CEO Craig Gulliford and CFO Richard Rees to increase the exercise price of their options, granted on 24 March 2025, from £0.13125 to £0.24 per share. All other terms of these options remain unchanged.
| Date | 9 Jul 2025 |
| Time | 09:41:07 |
| Category | Director/PDMR dealings |
| ID | 3572Q |
Creo Medical Group plc
("Creo", the "Company" or the "Group")
PDMR Options Revision
Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of minimally invasive surgical endoscopy for pre-cancer and cancer patients, announces that, following consultation with a number of significant shareholders, the Group's Board has undertaken to change the exercise price of options granted to certain PDMRs on 24 March 2025.
Accordingly, the Company has agreed with each of Craig Gulliford, CEO, and Richard Rees, CFO, that the exercise price in respect of the options granted to each of them on 24 March 2025 is increased from £0.13125 to £0.24 per share. All other terms of the Options remain the same.
This announcement has been approved for release by the Board of Creo Medical Group plc.
For further information please contact:
|
Creo Medical Group plc |
||
|
Richard Craven, Company Secretary |
Via Walbrook PR |
|
|
|
|
|
|
Deutsche Numis (Nominated Adviser, sole Broker and Financial Adviser) Freddie Barnfield / Duncan Monteith / Sher Shah |
+44 (0)20 7260 1000 |
|
|
|
|
|
|
Walbrook PR Ltd |
Tel: +44 (0)20 7933 8780 or [email protected] |
|
|
Paul McManus / Alice Woodings
|
Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 |
|
About Creo Medical
Creo is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.
The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation, and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less invasive and more cost-efficient option for procedures.
For more information, please refer to the website www.creomedical.com